KYNB · NASDAQ · Biotechnology

Kyntra Bio (KYNB)

Develops CD46-targeted cancer therapies and roxadustat for anemia in lower-risk myelodysplastic syndromes.

$7.24
vs last close−0.04 (−0.55%)